ArticleAmerican journal of hematology2017
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
Article in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00305175 (Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AI-assisted decision support for sickle cell disease severity stratification using routine blood tests: a systematic review and meta-analysis.BMC medical informatics and decision making · 2026Pooled it
- "Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?"Future science OA · 2026Article
- Evaluation of The Use of Hydroxyurea in Treating Children With Sickle Cell Anemia in Central Africa's Rural Area.EJHaem · 2026Article
- Retinal Challenges in Sickle Cell Patients-Present and Future: A Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Factors associated with hemoglobin response to hydroxyurea in patients with sickle cell disease.Blood red cells & iron · 2026Article
- Article
- Roxadustat induced fetal hemoglobin in anemic CKD patients: a dual-center real-world observational cohort study.BMC nephrology · 2026Observational
- Can platelet to neutrophil ratio (PNR) serve as a viable alternative tool for monitoring sickle cell disease patients on hydroxyurea in low income countries?Annals of hematology · 2025Article
- Impact of sickle cell anaemia on reproductive health: a narrative review.Reproductive health · 2025Review
- Article
- Social determinants of health affect disease severity among preschool children with sickle cell disease.Blood advances · 2024Article
- Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.Communications medicine · 2024Article
- Article
- Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease.Blood advances · 2024Article
- Randomized pilot trial of cell phone support to improve medication adherence among adolescents and young adults with chronic health conditions.BMC digital health · 2024Article
- miR-365-3p mediates BCL11A and SOX6 erythroid-specific coregulation: A new player in HbF activation.Molecular therapy. Nucleic acids · 2023Article
- Intensive hydroxyurea dosing in very young children with sickle cell anemia.Blood advances · 2023Article
- Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia.Blood advances · 2023Article
- Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.CPT: pharmacometrics & systems pharmacology · 2023Article
- TheJournal of pediatric genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hydroxyurea has proven clinical benefits and is recommended to be offered to all children with sickle cell anemia (SCA), but the optimal dosing regimen remains controversial. Induction of red blood cell fetal hemoglobin (HbF) by hydroxyurea appears to be dose-dependent. However, it is unknown whether maximizing HbF% improves clinical outcomes. HUSTLE (NCT00305175) is a prospective observational study with a primary goal of describing the long-term clinical effects of hydroxyurea escalated to maximal tolerated dose (MTD) in children with SCA. In 230 children, providing 610 patient-years of follow up, the mean attained HbF% at MTD was >20% for up to 4 years of follow-up. When HbF% values were ≤20%, children had twice the odds of hospitalization for any reason (P < .0001), including vaso-occlusive pain (P < .01) and acute chest syndrome (ACS) (P < .01), and more than four times the odds of admission for fever (P < .001). Thirty day readmission rates were not affected by HbF%. Neutropenia (ANC <1000 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.